

REMARKS


Applicants have canceled claim 4 and have added new claims 10 and 11. Applicants have amended claims 1-3 and 5-9 to conform with U.S. claim requirements. Attached hereto is a marked-up version of the changes made by the current amendment, captioned "Appendix to the Preliminary Amendment." Specifically, Applicants have clarified the claims, changed claim dependency, and provided proper antecedent basis support. No new matter has been added by these amendments and support for the changes made is in the original claims and the specification. Claims 1-3, and 5-11 are pending.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 10, 2003

By: 
Carol P. Einaudi
Reg. No. 32,220

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

APPENDIX TO THE PRELIMINARY AMENDMENT

1. A modified Factor VIII cDNA₁ wherein comprising:
an at least one intron, which is not an FVIII intron, has been inserted into
at least one location of the wild-type factor VIII cDNA, wherein said at least one intron is
not a factor VIII intron; and
characterized in that as a promoter a cDNA is used which is suitable for
targets the expression of said modified factor VIII cDNA to in hematopoietic cells lines
and specifically in platelets.
2. Modified Factor VIII cDNA as claimed in Claim 1, characterized in that
wherein the B-domain of the wild-type factor VIII cDNA has been deleted.
3. Modified Factor VIII cDNA as claimed in Claim 21, characterized in that
wherein said at least one the intron, which is not an FVIII intron, is a truncated factor IX
intron 1.
5. Modified Factor VIII cDNA as claimed in claim 41, characterized in that
wherein said as a promoter the cDNA coding for is the human platelet glycoprotein IIb
(GPIIb) promoter is used.
6. Modified Factor VIII cDNA as claimed in claim 41, characterized in that
wherein said at least one intron the truncated factor IX intron 1 has been inserted into
the wild-type factor VIII cDNA at the original positions of intron 1 and intron 13 of the
genomic Factor VIII DNA introns 1 + 13.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

7. A p~~P~~rocess for the production of Factor VIII, ~~characterized in that~~
comprising:
culturing a cell line under conditions suitable to produce a polypeptide
encoded by the production is performed in the cell line HEL or in the cell line Dami using
a modified Factor VIII cDNA as claimed in claim 1; and
recovering said polypeptide from the cell culture medium.
8. Process as claimed in claim 7, ~~characterized in that~~ wherein the
production of Factor VIII is stimulated by an inducer.
9. Process as claimed in claim 8, ~~characterized in that~~ wherein said as
inducer is phorbol-12-myristate-13-acetate (PMA) ~~is used.~~

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com